These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 29094152)

  • 1. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
    Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
    JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
    JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Butler J; Spertus JA; Hellkamp AS; Vaduganathan M; DeVore AD; Albert NM; Duffy CI; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    JAMA Cardiol; 2021 May; 6(5):522-531. PubMed ID: 33760037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.
    Yang M; Kondo T; Adamson C; Butt JH; Abraham WT; Desai AS; Jering KS; Køber L; Kosiborod MN; Packer M; Rouleau JL; Solomon SD; Vaduganathan M; Zile MR; Jhund PS; McMurray JJV
    Eur J Heart Fail; 2023 Sep; 25(9):1606-1618. PubMed ID: 37401511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes.
    Yee D; Novak E; Platts A; Nassif ME; LaRue SJ; Vader JM
    Am J Cardiol; 2019 Mar; 123(5):807-812. PubMed ID: 30587373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction.
    Angraal S; Mortazavi BJ; Gupta A; Khera R; Ahmad T; Desai NR; Jacoby DL; Masoudi FA; Spertus JA; Krumholz HM
    JACC Heart Fail; 2020 Jan; 8(1):12-21. PubMed ID: 31606361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure.
    Sepehrvand N; Savu A; Spertus JA; Dyck JRB; Anderson T; Howlett J; Paterson I; Oudit GY; Kaul P; McAlister FA; Ezekowitz JA;
    J Am Heart Assoc; 2020 Sep; 9(17):e017278. PubMed ID: 32812460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
    Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
    J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence.
    Huang W; Teng TK; Tay WT; Richards AM; Kadam U; Lawson CA; Shimizu W; Loh SY; Anand I; Lam CSP
    ESC Heart Fail; 2020 Oct; 7(5):2051-2062. PubMed ID: 32862518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.
    Peikert A; Chandra A; Kosiborod MN; Claggett BL; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Janssens SP; Belohlávek J; Borleffs CJW; Dobreanu D; Langkilde AM; Bengtsson O; Petersson M; McMurray JJV; Solomon SD; Vaduganathan M
    JAMA Cardiol; 2023 Jul; 8(7):684-690. PubMed ID: 37208998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.
    Joseph SM; Novak E; Arnold SV; Jones PG; Khattak H; Platts AE; Dávila-Román VG; Mann DL; Spertus JA
    Circ Heart Fail; 2013 Nov; 6(6):1139-46. PubMed ID: 24130003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Versus Physician-Assessed Health Status in Heart Failure With Reduced and Preserved Ejection Fraction From ASIAN-HF Registry.
    Teramoto K; Tay WT; Tromp J; Katherine Teng TH; Chandramouli C; Ouwerkerk W; Lawson CA; Huang W; Hung CL; Chopra V; Anand I; Mark Richards A; Lam CSP
    Circ Cardiovasc Qual Outcomes; 2023 Jan; 16(1):e009134. PubMed ID: 36484254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.
    Flint KM; Shah SJ; Lewis EF; Kao DP
    ESC Heart Fail; 2020 Jun; 7(3):811-824. PubMed ID: 32160420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
    Verma S; Butler J; Borlaug BA; Davies MJ; Kitzman DW; Petrie MC; Shah SJ; Jensen TJ; Rasmussen S; Rönnbäck C; Merkely B; O'Keefe E; Kosiborod MN;
    J Am Coll Cardiol; 2024 Oct; 84(17):1603-1614. PubMed ID: 39217565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between atrial fibrillation and heart failure patient reported outcomes across the ejection fraction spectrum.
    Elkholey K; Asad ZUA; Shehata E; Mustafina I; Fudim M; Stavrakis S
    Am Heart J; 2024 Jul; 273():61-71. PubMed ID: 38685463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation: COAPT Trial.
    Arnold SV; Stone GW; Mack MJ; Chhatriwalla AK; Austin BA; Zhang Z; Ben-Yehuda O; Kar S; Lim DS; Lindenfeld J; Abraham WT; Cohen DJ;
    J Am Coll Cardiol; 2020 May; 75(17):2099-2106. PubMed ID: 32194195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.